Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) Patents (Class 424/133.1)
Antibody, immunoglobulin, or fragment thereof fused via peptide linkage to nonimmunoglobulin protein, polypeptide, or fragment thereof (i.e., antibody or immunoglobulin fusion protein or polypeptide) (Class 424/134.1)
Single chain antibody (Class 424/135.1)
Bispecific or bifunctional, or multispecific or multifunctional, antibody or fragment thereof (Class 424/136.1)
  • Methods of treating pain and/or inflammatory disorders using lapatinib
    Patent number: 11103509
    Abstract: A method of treating pain is disclosed, which involves administering an effective amount of lapatinib or a pharmaceutically-acceptable salt thereof to a subject in need of treatment for pain.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: August 31, 2021
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Fang Zheng, Shuo Zhou, Ziyuan Zhou
  • Charged depth filtration of antigen-binding proteins
    Patent number: 11098079
    Abstract: Methods of producing an aqueous formulation of an antigen-binding protein or enhancing re-oxidation of an antigen-binding protein are disclosed. The methods comprise (a) contacting an aqueous solution comprising antigen-binding protein molecules with a charged depth filter under conditions sufficient to enhance re-oxidation of the antigen-binding protein molecules and achieve a decrease in the percentage of reduced antigen-binding protein molecules, compared to the percentage of reduced antigen-binding protein molecules observed prior to step (a); and (b) optionally, measuring the amount or relative amount of reduced antigen-binding protein molecules. Formulations comprising a re-oxidized antigen-binding protein are also described.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: August 24, 2021
    Assignee: AMGEN INC.
    Inventors: Hai Hoang, Rafael Gonzalez, Junfen Ma
  • Multi-specific binding molecules targeting aberrant cells
    Patent number: 11098115
    Abstract: Described are proteinaceous molecules comprising at least two, preferably three to six, binding domains that bind specifically to at least two different binding sites on aberrant cells. These multi-domain and multi-specific binding molecules are preferably used in selectively modulating biological processes. The provided binding molecules are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: August 24, 2021
    Assignee: APO-T B.V.
    Inventors: Ralph Alexander Willemsen, Johan Renes
  • Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
    Patent number: 11097005
    Abstract: Provided herein are methods and pharmaceutical compositions for the treatment of obesity-associated conditions using cadherin-11 antagonists.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: August 24, 2021
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Sook Kyung Chang, Lydia Lynch
  • Monoclonal antibodies against HER2
    Patent number: 11091553
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: August 17, 2021
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Edward N. Van Den Brink
  • Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
    Patent number: 11091543
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 17, 2021
    Assignee: Swedish Orphan Biovitrum AG
    Inventors: Cristina de Min, Walter Ferlin, Fabrizio De Benedetti
  • Thrombin inhibitors for treatment of stroke and related coagulative disorders
    Patent number: 11091535
    Abstract: The treatment of stroke related diseases are described herein. In addition, fibrin clot formation and related activity is proposed for the disclosed compounds, in particular, peptides for inhibiting or modifying the cleavages of fibrinogen by thrombin. Methods for producing such compounds are also disclosed.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: August 17, 2021
    Assignee: THE UNIVERSITY OF SYDNEY
    Inventors: Richard J. Payne, Shaun Phillip Jackson, Pedro Jose Barbosa Pereira
  • Human FcRn-binding modified antibodies and methods of use
    Patent number: 11091541
    Abstract: Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: August 17, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Guido Hartmann, Joerg Thomas Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer
  • Methods for diagnosing and treating inflammatory bowel disease
    Patent number: 11091551
    Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: August 17, 2021
    Assignee: Genentech, Inc.
    Inventors: Mary Keir, Gaik Wei Tew
  • Method for isolation of soluble polypeptides
    Patent number: 11091536
    Abstract: Polypeptides with biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human heavy and light chain variable domains (VHs and VLs), are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library phage, and identifying phage which form larger than average plaques on the bacterial lawn. Sequences of monomeric human VHs and VLs are identified, which may be useful for immunotherapy or as diagnostic agents. Multimer complexes of human VHs and VLs are also identified. The VHs and VLs identified may be used to create further libraries for identifying additional polypeptides. Further, the VHS and VLs may be subjected to DNA shuffling to select for improved biophysical properties.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: August 17, 2021
    Assignee: NATIONAL RESEARCH COUNCIL OF CANADA
    Inventor: Jamshid Tanha
  • Ovarian cancer vaccines
    Patent number: 11090284
    Abstract: Provided herein are methods, kits and compositions for the treatment and/or prevention of ovarian cancer through the induction of an immune response against Anti-Mullerian Hormone Receptor, Type II (AMHR2).
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: August 17, 2021
    Assignee: The Cleveland Clinic Foundation
    Inventors: Vincent K. Tuohy, Suparna Mazumder, Justin M. Johnson
  • HER-2 binding antibodies
    Patent number: 11091561
    Abstract: The present invention relates to monoclonal antibodies that specifically bind to HER2, or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer specific HER2 binding to the polypeptide. Said antibodies bind to the human Fc receptor and induce FcR mediated signaling pathways. The antibodies according to the invention bind to a different epitope than trastuzumab. The invention also relates to the use of an antibody according to the invention in the treatment of a HER-2 mediated disease. The present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention, and the use of said composition in the treatment of a HER-2 mediated disease.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: August 17, 2021
    Assignee: MAB DISCOVERY GMBH
    Inventors: Stephan Fischer, Michael Brandt
  • Anti-podocalyxin antibodies and methods of using the same
    Patent number: 11090383
    Abstract: The present invention is directed to anti-podocalyxin antibodies, compositions comprising the same, and methods of using such antibodies and compositions for the prevention, diagnosis and treatment of cancer.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: August 17, 2021
    Inventors: Kelly Marshall McNagny, Calvin D. Roskelley, Michael R. Hughes, Diana Canals Hernaez, Klas Ola Blixt, John Stephen Babcook, Christopher John Bond, Ismael Samudio, Jan Peter Bergqvist, Katherine Grace MacDonald, Anna Von Rossum, Bradley John Hedberg, Pamela Megan Dean
  • Coiled-coil connector
    Patent number: 11090381
    Abstract: A connector of a helical coiled coil-type structure connecting a first and a second molecule, wherein the first molecule comprises a peptidic first alpha-helix and the second molecule comprises a peptidic second alpha-helix, which second alpha-helix is coiled to the first alpha-helix. The first alpha-helix comprises a C-terminal region consisting of a repeat of an amino acid motif a-x1 and the C-terminal motif a-x1-x2, or an N-terminal region consisting of a repeat of an amino acid motif x1-a and the N-terminal motif x2-x1-a, where a is a motif sequence of 4-8 amino acids, x1 is Lysine, and x2 is an extension of the motif. The extension consists of 1-10 amino acids and does not comprise more than 4 consecutive amino acids incorporated in said motif a-x1 or x1-a. In a multimeric protein, two polypeptide chains can be connected to each other by such connector.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: August 17, 2021
    Assignee: ONCOQR ML GMBH
    Inventors: Geert Mudde, Jorge Sepulveda, Christopher Taus, Liesbeth Mudde-Boer
  • Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
    Patent number: 11084868
    Abstract: Libraries of immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: August 10, 2021
    Assignee: F-star Biotechnologische Forschungs- und Entwicklungsges M.B.H.
    Inventors: Gottfried Himmler, Florian Ruker, Gordana Wozniak-Knopp
  • Siglec-10 antibodies
    Patent number: 11083785
    Abstract: This disclosure relates to agents that bind and neutralize the inhibitory activity of Siglec-10 in lymphocytes, notably by inhibiting the binding of Siglec-10 to its sialic acid ligands on target cells, notably tumor cells. Such agents can be used for the treatment of cancers.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 10, 2021
    Assignee: INNATE PHARMA
    Inventors: Stephanie Cornen, Laurent Gauthier, Benjamin Rossi, Nicolai Wagtmann
  • Gene mutations and copy number alterations of EGFR, KRAS and MET
    Patent number: 11085086
    Abstract: Sequence variants and copy number variations in the EGFR, KRAS and MET genes are biomarkers for resistance to anti-EGFR therapies for cancer. This disclosure provides methods of detecting these biomarkers and using them in the diagnosis and treatment of cancer.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: August 10, 2021
    Assignee: Guardant Health, Inc.
    Inventors: Scott Kopetz, AmirAli Talasaz
  • Combination therapy for the treatment of cancer
    Patent number: 11078279
    Abstract: This invention relates to a pharmaceutical composition that comprises a first molecule that specifically binds HER2/neu and a second molecule that specifically binds a cell-surface receptor (or its ligand) that is involved in regulating an immune checkpoint (or the ligand thereof). The invention particularly relates to the embodiment wherein the second molecule binds to PD-1. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: August 3, 2021
    Assignee: MacroGenics, Inc.
    Inventors: Jon Marc Wigginton, Naimish Bharat Pandya, Robert Joseph Lechleider, Scott Koenig, Ezio Bonvini
  • Adjuvant treatment of HER2-positive breast cancer
    Patent number: 11077189
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: August 3, 2021
    Assignees: Genentech Inc., Hoffmann La-Roche Inc.
    Inventors: Mark C. Benyunes, Graham Alexander Ross
  • Anti-tumor T cell immunity induced by high dose radiation
    Patent number: 11077141
    Abstract: Cancer treatment is provided, by irradiating an individual with a localized, high single dose or short course of doses at a primary tumor site; collecting T cells from the individual after a period of time sufficient activation of an anti-tumor response; treating the individual with an effective dose of dose of chemotherapy; and reintroducing the T cell population back to the individual.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: August 3, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Samuel Strober, Alexander Filatenkov
  • Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
    Patent number: 11071780
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: July 27, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. Vitti, Kristine A. Erickson, Karen W. Chu, Stanley J. Wiegand, Jingtai Cao, Ivan B. Lobov, Saurabh Wadhwa, Kenneth S. Graham, Daniel Dix
  • Combination immunotherapy for treating cancer
    Patent number: 11071775
    Abstract: A method is disclosed for treating small cell lung cancer (SCLC) in a subject that involves administering to the subject a therapeutically effective amount of dendritic cells engineered to overexpress p53. In some embodiments, the method further involves administering to the subject a therapeutically effective amount of all-trans-retinoic acid (ATRA). The method can also involve administering to the subject a therapeutically effective amount of an immune checkpoint inhibitor.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: July 27, 2021
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventor: Scott Antonia
  • Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
    Patent number: 11066475
    Abstract: Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: July 20, 2021
    Assignees: Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center
    Inventors: Blythe D. Sather, Eric L. Smith, Rupesh Amin, Aye Chen, Kimberly Harrington, Collin Hauskins, Erik Hess, Cyr De Imus, Jon Jones, Audrey Olshefsky, Stefan Ponko, Ruth Salmon, Semih Tareen, Rebecca Wu, Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons, Mariana Cota Stirner, Melissa Works
  • Use of EZH2 inhibitor combined with BTK inhibitor in preparing drug for treating tumor
    Patent number: 11065239
    Abstract: This application describes a use of an EZH2 inhibitor combined with a BTK inhibitor in preparing a drug for treating a tumor is described.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: July 20, 2021
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Ke Ma, Guoqing Cao, Changyong Yang, Lianshan Zhang
  • IgG Fc fragment for a drug carrier and method for the preparation thereof
    Patent number: 11058776
    Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: July 13, 2021
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Sung Youb Jung, Jin Sun Kim, Geun Hee Yang, Se Chang Kwon, Gwan Sun Lee
  • Inhibitors of cytoplasmic histone deacetylase 4 complex for treating or preventing vascular or valve calcification
    Patent number: 11060092
    Abstract: A pharmaceutical composition and a method of treating, reducing or preventing vascular, cardiovascular arterial or valve calcification in a subject in need comprising administering to the subject an effective amount of an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof is provided. In some embodiments, there is provided a pharmaceutical composition comprising: an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof; an agent that prevents or reduces the expression of SIK or is an inhibitor of SIK; and/or an agent that prevents or reduces the expression of ENIGMA (Pdlim7) or is an inhibitor of ENIGMA.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: July 13, 2021
    Assignees: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, RAMBAM MED-TECH LTD.
    Inventors: Izhak Kehat, Alon Abend, Omer Shkedi, Lilac Caspi
  • Sequence symmetric modified IgG4 bispecific antibodies
    Patent number: 11059911
    Abstract: The present disclosure relates to a symmetric bispecific antibody of the class IgG4 comprising two heavy chains which each comprise a variable domain, CH1 domain and a hinge region, wherein in each heavy chain: the cysteine in the CH1 domain which forms an inter-chain disulphide bond with a cysteine in a light chain is substituted with another amino acid; and optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, wherein the constant region sequence of each heavy chain is similar or identical and the variable region in each heavy chain is different, formulations comprising the same, the use of each of the above in treatment and processes for preparing said antibodies and formulations.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: July 13, 2021
    Assignee: UCB Biopharma SRL
    Inventors: David Paul Humphreys, Shirley Jane Peters
  • Engineered IgA antibodies and methods of use
    Patent number: 11059909
    Abstract: Provided herein are engineered antibodies that comprise a modified IgA heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitution or deletion in a constant region of an IgA domain. Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: July 13, 2021
    Assignee: UMC UTRECHT HOLDING B.V.
    Inventors: Jeanette Henrica Wilhelmina Leusen, Johannes Gerardus Maria Evers, Geert Jan Van Tetering
  • Methods and materials for assessing and treating cancer
    Patent number: 11060150
    Abstract: This document provides methods and materials involved in assessing cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) having ER?/PgR?/HER2? cancer cells is likely to have a favorable or unfavorable outcome and/or is likely to respond a cancer treatment that includes a PD-1 inhibitor and/or PD-L1 inhibitor in combination with a JAK2 inhibitor are provided. Methods and materials involved in treating mammals having ER?/PgR?/HER2? cancer (e.g., ER?/PgR?/HER2? breast cancer) by administering a PD-1 inhibitor and/or PD-L1 inhibitor in combination with a JAK2 inhibitor also are provided.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: July 13, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Barbara A. Pockaj, Michael T. Barrett, Mitesh J. Borad, Karen S. Anderson, Ramesh K. Ramanathan
  • Allogeneic tumor cell vaccine
    Patent number: 11058752
    Abstract: The described invention provides a tumor cell vaccine comprising genetically modified tumor cell line of a particular tumor type that stably expresses high levels of two or more immunomodulators. According to some embodiments, an immunogenic amount of the tumor cell line variants may be selected for concomitant expression of two or more of recombinant membrane expressed IgG1, CD40L, TNF-alpha, as well as membrane and soluble forms of GM-CSF, and Flt-3L peptides that are effective to elicit an anti-tumor immune response compared to the parent unmodified tumor cell line as measured in vitro by a one-way mixed lymphocyte tumor reaction assay using human peripheral blood mononuclear cells and the genetically modified allogeneic cell vaccine candidate.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: July 13, 2021
    Assignee: ALLOPLEX BIOTHERAPEUTICS
    Inventor: Frank Borriello
  • Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab
    Patent number: 11058769
    Abstract: The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: July 13, 2021
    Assignees: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Gianluca Rinaldi, Alessandra Del Rio, Silvia Fratar-Cangeli, Senta Voss, Markus Weigandt
  • Engineered antibody Fc variants for enhanced serum half life
    Patent number: 11059892
    Abstract: In some aspects, mutant or variant Fc domains are provided that exhibit increased binding to FcRn and increased half-life after administration in vivo. The Fc domain may be comprised in a glycosylated or aglycosylated antibody. Methods for using the mutant or variant Fc domains or polypeptides comprising the mutant or variant Fc domains are also provided.
    Type: Grant
    Filed: August 11, 2018
    Date of Patent: July 13, 2021
    Assignee: Research Development Foundation
    Inventors: George Georgiou, Chang-Han Lee, Tae Hyun Kang
  • Modified antibodies containing modified IGG2 domains which elicit agonist or antagonistic properties and use thereof
    Patent number: 11059898
    Abstract: Through a combination of in vitro and in vivo approaches, the inventors show that human IgG2 (h2) delivers unique Fc?R-independent agonistic activity to anti-CD40 antibodies and to antibodies specific to other immunostimulatory receptors, including 4-1BB and CD28. Investigation of an anti-human CD40 mAb, LOB7.4, revealed that the unique activity of h2 was dependent upon the precise arrangement of hinge and CH1 disulfide bonds. Chemical ‘shuffling’ or mutagenesis to ‘lock’ LOB7.4 into either a more flexible ‘h2A’ or more compact ‘h2B’ conformation endowed antagonistic and agonistic properties, respectively. Engineering of h2 in this way allows development of reagents with either immunostimulatory or immunosuppressive characteristics, with direct implication for the design of therapeutic mAb agents and fusion proteins.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: July 13, 2021
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Martin J. Glennie, Ann White
  • System and methods for massively parallel analysis of nucleic acids in single cells
    Patent number: 11053543
    Abstract: Methods and systems are provided for massively parallel genetic analysis of single cells in emulsion droplets or reaction containers. Genetic loci of interest are targeted in a single cell using a set of probes, and a fusion complex is formed by molecular linkage and amplification techniques. Methods are provided for high-throughput, massively parallel analysis of the fusion complex in a single cell in a population of at least 10,000 cells. Also provided are methods for tracing genetic information back to a cell using barcode sequences.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: July 6, 2021
    Assignee: GigaGen, Inc.
    Inventors: David Scott Johnson, Everett Hurteau Meyer
  • Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
    Patent number: 11053318
    Abstract: The present invention provides a bispecific construct comprising a first binding domain specifically binding to CD33 and a second binding domain specifically binding to CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered for a maximal period of 14 days followed by a period of at least 14 days without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific construct and the use of such bispecific construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: July 6, 2021
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Gerhard Zugmaier, Peter Kufer, Roman Kischel, Marion Subklewe, Christina Heitmueller
  • Anti-LAG3 antibodies and antigen-binding fragments
    Patent number: 11045547
    Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: June 29, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Rene De Waal Malefyt, Laurence Fayadat-Dilman, Linda Liang
  • Anti-podocalyxin antibody that targets tumor microenvironment
    Patent number: 11046778
    Abstract: The present invention provides a cancer microenvironment-targeting anti-podocalyxin antibody or antigen binding fragment thereof.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: June 29, 2021
    Assignees: TOHOKU UNIVERSITY, ZENOAQ RESOURCE CO., LTD.
    Inventors: Yukinari Kato, Mika Kato, Satoshi Ogasawara
  • Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a human sample
    Patent number: 11047864
    Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: June 29, 2021
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
  • Monoclonal antibodies against HER2
    Patent number: 11046771
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: June 29, 2021
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Edward N. Van Den Brink
  • Antibody based reagents that specifically recognize toxic oligomeric forms of tau
    Patent number: 11046755
    Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomeric tau, fibrillar tau or non-disease associated forms of tau.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: June 29, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Huilai Tian
  • Human neuregulin-1 (NRG-1) recombinant fusion protein compositions and methods of use thereof
    Patent number: 11046741
    Abstract: The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone and to a method of treating a disease or condition in a subject in need thereof comprising administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition comprising the recombinant fusion protein disclosed herein.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: June 29, 2021
    Assignees: Salubris Biotherapeutics, Inc., Salubris (Chengdu) Biotech Co., Ltd.
    Inventors: John Li, Shengwei Li, Dixiang Luo, Yiran Wu, Ming Zhou, Xiaolei Zhuang, Liang Hua, Pengyi Luo, Yang Wang
  • Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
    Patent number: 11041861
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which, comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: June 22, 2021
    Assignee: INBIOMOTION S.L.
    Inventors: Roger Gomis, Joël Jean-Mairet
  • Crystal form of indole derivative and preparation method and use thereof
    Patent number: 11034681
    Abstract: Disclosed are a crystal form of an indole derivative (compound 1) and a pharmaceutical composition and preparation method thereof. The crystal form is used to prepare a drug for treating a disease related to a CRTH2 receptor.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: June 15, 2021
    Inventors: Yuanshan Yao, Bin Chen, Feng Gao, Yuan Chen, Ran Xu, Chengshuai Yang, Sheng Zhang, Jian Li, Shuhui Chen
  • Anti-CTLA4 antibodies and uses thereof
    Patent number: 11034764
    Abstract: This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: June 15, 2021
    Assignee: Eucure (Beijing) Biopharma Co., Ltd
    Inventors: Yi Yang, Yanan Guo, Xiaodong Cheng, Yunyun Chen, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni
  • Flag tagged CD19-CAR-T cells
    Patent number: 11034763
    Abstract: The present invention provides chimeric antigen receptor (CAR)-T cells modified to express a CAR fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv has an activity against a tumor antigen CD19, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain; wherein the fusion protein further comprises a FLAG tag N-terminus to scFv, C-terminus to scFv, or between VH and VL. Using CD19-FLAG CAR-T cells instead of CD19 CAR-T cells, cytokine levels (Interferon-?, IL-2 and IL6) caused by infused CAR-T cells are reduced.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: June 15, 2021
    Assignees: ProMab Biotechnologies, Inc., Forevertek Biotechnology Co., Ltd.
    Inventors: Lijun Wu, Vita Golubovskaya, Martyn Lewis, Hua Zhou
  • Polypeptides antagonizing Wnt signaling in tumor cells
    Patent number: 11033636
    Abstract: The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: June 15, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Vittoria Zinzalla, Klaus-Peter Kuenkele, Marie-Ange Buyse, Karen Cromie, Stephanie Staelens, Beatrijs Strubbe
  • Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers
    Patent number: 11034760
    Abstract: Methods and compositions for treating hemophagocytic lymphohistiocytosis (HLH) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of CXCL9, elevated levels of total IFN?, and other biomarkers. The disclosure also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder in patients with elevated levels of CXCL9 elevated levels of total IFN?, and other biomarkers using agents that interfere with or otherwise antagonize interferon gamma (IFN?) signaling, including neutralizing anti-IFN? antibodies.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: June 15, 2021
    Assignee: Swedish Orphen Biovitrum AG
    Inventors: Cristina de Min, Walter Ferlin, Fabrizio De Benedetti
  • Single domain binding molecule
    Patent number: 11034756
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: June 15, 2021
    Assignee: ELASMOGEN LIMITED
    Inventors: Caroline Barelle, Mischa Roland Muller, Valarie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • High affinity MAGE-A1-specific TCRs and uses thereof
    Patent number: 11034748
    Abstract: The present disclosure provides TCRs with high or enhanced affinity against various tumor associated antigens (including human MAGE-A1 epitopes), T cells expressing such high affinity antigen-specific TCRs, nucleic acids encoding the same, and compositions for use in treating diseases or disorders in which cells overexpress one or more of these antigens, such as in cancer.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: June 15, 2021
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Aude Chapuis, Thomas Schmitt, Megan McAfee
  • Nucleic acid encoding anti-GM-CSF antibodies
    Patent number: 11028165
    Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: June 8, 2021
    Assignee: MORPHOSYS AG
    Inventors: Stefan Steidl, Elisabeth Thomassen-Wolf